A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Roos J. Jutten, John Harrison, Philippe R. Lee Meeuw Kjoe, Esther M. Opmeer, Niki S.M. Schoonenboom, Frank Jan de Jong, Craig W. Ritchie, Philip Scheltens, Sietske A.M. Sikkes

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
167 Downloads (Pure)

Abstract

Introduction To improve the detection of changes in Alzheimer's disease, we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment or mild Alzheimer's disease dementia and cognitively healthy participants. We calculated intraclass correlation coefficients type absolute agreement for all CFC measures and compared baseline and retest scores using paired sample t-tests. We evaluated feasibility by interviewing participants. Results Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Conclusions The CFC is a stable and feasible measure in mild cognitive impairment and mild Alzheimer's disease, and thereby meets important quality metrics for clinically meaningful outcome measures.
Original languageEnglish
Pages (from-to)153-160
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume10
DOIs
Publication statusE-pub ahead of print - 27 Dec 2017

Keywords

  • Activities of daily living
  • Alzheimer's disease
  • Cognition
  • Feasibility
  • Test–retest reliability
  • Outcome measures

Fingerprint

Dive into the research topics of 'A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility'. Together they form a unique fingerprint.

Cite this